clofibric acid has been researched along with Cardiometabolic Syndrome in 40 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited." | 4.82 | Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005) |
| " In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats." | 3.74 | Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008) |
| "The metabolic syndrome is defined as a clustering of cardiovascular risk factors with insulin resistance, including dyslipidemia, coagulation disturbances and hypertension." | 2.44 | Measuring biomarkers to assess the therapeutic effects of PPAR agonists? ( Chinetti-Gbaguidi, G; Staels, B, 2007) |
| "The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension." | 2.43 | Therapeutical effects of PPAR agonists assessed by biomarker modulation. ( Chinetti-Gbaguidi, G; Fruchart, JC; Staels, B, 2005) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "Patients with metabolic syndrome and type 2 diabetes mellitus are usually in moderately high-risk, high-risk, or very high-risk cardiovascular categories and present major therapeutic challenges." | 2.43 | Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. ( Dayspring, T; Pokrywka, G, 2006) |
| "The metabolic syndrome is commonly encountered in the United States." | 2.42 | Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. ( Reasner, CA; Rosenson, RS, 2004) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "The metabolic syndrome is a cluster of symptoms that function as risk factors for cardiovascular disease (CVD), and its key components--diabetes, dyslipidemia, and hypertension--form a lethal combination." | 1.36 | Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. ( Mehta, A, 2010) |
| "Adult patients with type 1 diabetes mellitus (n = 533; 256 men, 277 women; age: 35." | 1.35 | [Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus]. ( Fövényi, J; Gaál, Z; Gyimesi, A; Hídvégi, T; Hosszúfalusi, N; Jermendy, G; Nádas, J; Neuwirth, G; Oroszlán, T; Pánczél, P; Putz, Z; Vándorfi, G; Winkler, G; Wittmann, I, 2008) |
| "Likewise, the metabolic syndrome is a secondary target of treatment." | 1.32 | CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management. ( Thompson, PD, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (95.00) | 29.6817 |
| 2010's | 2 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nádas, J | 1 |
| Putz, Z | 1 |
| Fövényi, J | 1 |
| Gaál, Z | 1 |
| Gyimesi, A | 1 |
| Hídvégi, T | 1 |
| Hosszúfalusi, N | 1 |
| Neuwirth, G | 1 |
| Oroszlán, T | 1 |
| Pánczél, P | 1 |
| Vándorfi, G | 1 |
| Winkler, G | 1 |
| Wittmann, I | 1 |
| Jermendy, G | 1 |
| Lupp, A | 1 |
| Karge, E | 1 |
| Deufel, T | 1 |
| Oelschlägers, H | 1 |
| Fleck, C | 1 |
| Edavalath, M | 1 |
| Rees, A | 1 |
| Toth, PP | 1 |
| Davidson, M | 1 |
| Hughes, S | 1 |
| Montecucco, F | 1 |
| Mach, F | 1 |
| Wierzbicki, AS | 1 |
| Thompson, PD | 1 |
| Ginsberg, HN | 1 |
| Maccallum, PR | 1 |
| Cybulska, B | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Davidson, MH | 3 |
| Nakajima, K | 1 |
| Mehta, A | 1 |
| Robins, SJ | 1 |
| Rosenson, RS | 1 |
| Reasner, CA | 1 |
| Rabasseda, X | 1 |
| Benz, R | 1 |
| Suter, PM | 1 |
| Staels, B | 3 |
| Fruchart, JC | 2 |
| Vergès, B | 1 |
| Kastelein, JJ | 1 |
| Chinetti-Gbaguidi, G | 2 |
| Turhan, H | 1 |
| Yetkin, E | 1 |
| Moser, M | 1 |
| Falkner, B | 1 |
| Weber, MA | 1 |
| Keilson, LM | 1 |
| Paragh, G | 1 |
| Seres, I | 1 |
| Harangi, M | 1 |
| Erdei, A | 1 |
| Audikovszky, M | 1 |
| Debreczeni, L | 1 |
| Kovácsay, A | 1 |
| Illyés, L | 1 |
| Pados, G | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Soska, V | 1 |
| Dayspring, T | 1 |
| Pokrywka, G | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Motro, M | 1 |
| Adler, Y | 1 |
| Konstantinov, VO | 1 |
| Saĭfulina, IaR | 1 |
| Ascaso, J | 1 |
| Gonzalez Santos, P | 1 |
| Hernandez Mijares, A | 1 |
| Mangas Rojas, A | 1 |
| Masana, L | 1 |
| Millan, J | 1 |
| Pallardo, LF | 1 |
| Pedro-Botet, J | 1 |
| Perez Jimenez, F | 1 |
| Pintó, X | 1 |
| Plaza, I | 1 |
| Rubiés, J | 1 |
| Zúñiga, M | 1 |
| Tada, N | 1 |
| Sposito, AC | 1 |
| Caramelli, B | 1 |
| Fonseca, FA | 1 |
| Bertolami, MC | 1 |
| Afiune Neto, A | 1 |
| Souza, AD | 1 |
| Lottenberg, AM | 1 |
| Chacra, AP | 1 |
| Faludi, AA | 1 |
| Loures-Vale, AA | 1 |
| Carvalho, AC | 1 |
| Duncan, B | 1 |
| Gelonese, B | 1 |
| Polanczyk, C | 1 |
| Rodrigues Sobrinho, CR | 1 |
| Scherr, C | 1 |
| Karla, C | 1 |
| Armaganijan, D | 1 |
| Moriguchi, E | 1 |
| Saraiva, F | 1 |
| Pichetti, G | 1 |
| Xavier, HT | 1 |
| Chaves, H | 1 |
| Borges, JL | 1 |
| Diament, J | 1 |
| Guimarães, JI | 1 |
| Nicolau, JC | 1 |
| dos Santos, JE | 1 |
| de Lima, JJ | 1 |
| Vieira, JL | 1 |
| Novazzi, JP | 1 |
| Faria Neto, JR | 1 |
| Torres, KP | 1 |
| Pinto, Lde A | 1 |
| Bricarello, L | 1 |
| Bodanese, LC | 1 |
| Introcaso, L | 1 |
| Malachias, MV | 1 |
| Izar, MC | 1 |
| Magalhães, ME | 1 |
| Schmidt, MI | 1 |
| Scartezini, M | 1 |
| Nobre, M | 1 |
| Foppa, M | 1 |
| Forti, NA | 1 |
| Berwanger, O | 1 |
| Gebara, OC | 1 |
| Coelho, OR | 1 |
| Maranhão, RC | 1 |
| dos Santos Filho, RD | 1 |
| Costa, RP | 1 |
| Barreto, S | 1 |
| Kaiser, S | 1 |
| Ihara, S | 1 |
| Carvalho, Td | 1 |
| Martinez, TL | 1 |
| Relvas, WG | 1 |
| Salgado, W | 1 |
| Zvenigorodskaia, LA | 1 |
| Mel'nikova, NV | 1 |
| Bondarenko, EIu | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Ballantyne, CM | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial[NCT02463435] | 229 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
26 reviews available for clofibric acid and Cardiometabolic Syndrome
| Article | Year |
|---|---|
When high is low: raising low levels of high-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; | 2008 |
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, | 2008 |
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2009 |
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Me | 2009 |
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli | 2009 |
[Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Topics: Clofibric Acid; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; | 2005 |
Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type | 2010 |
Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Topics: Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; | 2003 |
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-Co | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric A | 2004 |
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Inflamm | 2005 |
Management of dyslipidemia in patients with complicated metabolic syndrome.
Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co | 2005 |
Role for fibrate therapy in diabetes: evidence before FIELD.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Metabolic Sy | 2005 |
Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Topics: Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Clofibric Acid; Humans; Inflammation; | 2005 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
[Nuclear receptors PPARalpha].
Topics: Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabo | 2006 |
Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypol | 2006 |
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxy | 2006 |
[Cardiovascular risk and possibilities of lowering it in patients with metabolic syndrome and type II diabetes mellitus. The role of fibrates].
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Me | 2006 |
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Topics: Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2007 |
[Fibrate and its perspective as a drug for metabolic syndrome].
Topics: Anticholesteremic Agents; Clofibric Acid; Humans; Hypolipidemic Agents; Metabolic Syndrome | 2006 |
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypertriglyceridemia; Hypolipidem | 2008 |
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylg | 2007 |
Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Topics: Animals; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Meta | 2007 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
1 trial available for clofibric acid and Cardiometabolic Syndrome
| Article | Year |
|---|---|
[Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
Topics: Carbohydrate Metabolism; Clofibric Acid; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 2007 |
13 other studies available for clofibric acid and Cardiometabolic Syndrome
| Article | Year |
|---|---|
[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus].
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Blood Pressure; Body Mass Inde | 2008 |
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym | 2008 |
Therapy and clinical trials: metabolic syndrome and cardiovascular risk management.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Hydroxymethylgluta | 2008 |
On the road to better dyslipidemia outcomes.
Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hy | 2009 |
CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management.
Topics: Adult; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Dyslipidemias; Fe | 2003 |
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
Topics: Animals; Betaine; Bezafibrate; Clofibric Acid; Dyslipidemias; Folic Acid; Homocysteine; Humans; Hypo | 2009 |
Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductas | 2010 |
Highlights from the 74th Congress of the European Atherosclerosis Society.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Cholesterol; Clofibric Acid; Humans; Hydroxymeth | 2004 |
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric | 2005 |
Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Topics: Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic | 2006 |
The metabolic syndrome--what is it and how should it be managed?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
Topics: Aryldialkylphosphatase; Case-Control Studies; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans | 2006 |
[IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology].
Topics: Adult; Age Distribution; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Diet; Female; H | 2007 |